Early toxicity of moderately hypofractionated radiation therapy in breast cancer patients receiving locoregional irradiation: First results of the UNICANCER HypoG-01 phase III trial.

Date publication

mars 2025

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CLAVIER Jean-Baptiste , Dr PEIGNAUX Karine

Tous les auteurs :
Brion T, Ghodssighassemabadi R, Auzac G, Kirova Y, Racadot S, Benchalal M, Clavier JB, Brunaud C, Fouche-Chand ME, Argo-Leignel D, Peignaux-Casasnovas K, Benyoucef A, Pasquier D, Guilbert P, Blanchecotte J, Tallet-Richard A, Lamrani A, Bergeau M, Bielynite G, Ruffier A, Karamouza E, Michiels S, Rivera S

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/40097073

Résumé

To investigate early adverse events (AEs) in HypoG-01, a randomised, controlled, multicentre, non-inferiority phase 3 trial comparing toxicity and efficacy of adjuvant loco-regional moderately hypofractionated radiation therapy versus 2 Gy daily radiation therapy.

Mots clés

Breast cancer, Early toxicity, Hypofractionation, Radiation therapy

Référence

Radiother Oncol. 2025 03 15;:110849